ALNY Key Stats
- On The Fly: Analyst Initiation Summary May 24
- Deutsche Bank Starts Alnylam Pharmaceuticals (ALNY) at Buy Street Insider May 24
- Alnylam Pharmaceuticals' Management Presents at 2013 UBS Global Healthcare Confe... May 22
- Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Car... May 21
- Alnylam announces proof-of-concept data from RNAi program May 17
- Alnylam (ALNY) Updates on Preclinical Data for RNAi Program Targeting ALAS-1 Street Insider May 17
- InPlay: Alnylam Pharma presents key pre-clinical proof-of-concept data for ALN-A... May 17
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi The... May 17
- Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Heal... May 16
- Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference Business Wire May 15
ALNY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alnylam Pharmaceuticals is up 198.1% over the last year vs S&P 500 Total Return up 27.96%, Targacept up 33.61%, and Isis Pharmaceuticals up 118.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ALNY
Pro Report PDF for ALNY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ALNY Pro Report PDF
Pro Strategies Featuring ALNY
Did Alnylam Pharmaceuticals make it into our Pro Portfolio Strategies?